Journal Article > ReviewFull Text
Curr Opin HIV AIDS. 2019 January 1; Volume 14 (Issue 1); DOI:10.1097/COH.0000000000000514
Khwairakpam G, Burry J
Curr Opin HIV AIDS. 2019 January 1; Volume 14 (Issue 1); DOI:10.1097/COH.0000000000000514
With increasing availability of generic direct-acting antivirals (DAAs) and associated price reductions, various governments, multilateral institutions, and donors have started providing testing and treatment for hepatitis C virus (HCV) infection. More data on the quality of these generic medicines and on cost-effectiveness of their use are becoming widely available. This review seeks to describe some of the treatment programs for HCV that are evolving in Cambodia, India, Indonesia, Malaysia, Myanmar, and Thailand.